CU20120157A7 - Heterociclilbencilpirazoles sustituidos y uso de los mismos - Google Patents

Heterociclilbencilpirazoles sustituidos y uso de los mismos

Info

Publication number
CU20120157A7
CU20120157A7 CU2012000157A CU20120157A CU20120157A7 CU 20120157 A7 CU20120157 A7 CU 20120157A7 CU 2012000157 A CU2012000157 A CU 2012000157A CU 20120157 A CU20120157 A CU 20120157A CU 20120157 A7 CU20120157 A7 CU 20120157A7
Authority
CU
Cuba
Prior art keywords
diseases
prevention
treatment
heterociclilbencilpirazoles
replaced
Prior art date
Application number
CU2012000157A
Other languages
English (en)
Inventor
Michael Härter
Hartmut Beck
Susanne Greaschat
Peter Ellinghaus
Kerstin Berhörster
Joachim Schuhmacher
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120157(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20120157A7 publication Critical patent/CU20120157A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a derivados de 1-[3-(heterociclil)bencil]-1H-pirazol novedosos, a procedimientos para su ptreparación, a su uso para el tratamiento y/o la prevención de enfermedades y a su uso para la producción de medicamentos para el tratamiento y/o la prevención de enfermedades, más particularmente para el tratamiento y/o la prevención de enfermedades hiperproliferativas y angiogénicas y las enfermedades que se originan de la adaptación metabólica a estados hipóxicos.Tales tratamientos se pueden llevar a cabo en forma de monoterapia o también en combinación con otros mediacemntos o medidas terapéuticas adicionales.
CU2012000157A 2010-05-08 2012-11-07 Heterociclilbencilpirazoles sustituidos y uso de los mismos CU20120157A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004855 2010-05-08
PCT/EP2011/057021 WO2011141326A1 (de) 2010-05-08 2011-05-03 Substituierte heterocyclylbenzyl-pyrazole und ihre verwendung

Publications (1)

Publication Number Publication Date
CU20120157A7 true CU20120157A7 (es) 2013-03-27

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000157A CU20120157A7 (es) 2010-05-08 2012-11-07 Heterociclilbencilpirazoles sustituidos y uso de los mismos

Country Status (25)

Country Link
US (2) US20130172311A1 (es)
EP (1) EP2569312B1 (es)
JP (1) JP5727002B2 (es)
KR (1) KR20130108997A (es)
CN (1) CN103003269B (es)
AR (1) AR081368A1 (es)
AU (1) AU2011252223A1 (es)
BR (1) BR112012028651A2 (es)
CA (1) CA2798375A1 (es)
CO (1) CO6640218A2 (es)
CR (1) CR20120570A (es)
CU (1) CU20120157A7 (es)
DO (1) DOP2012000284A (es)
EA (1) EA201291167A1 (es)
EC (1) ECSP12012288A (es)
ES (1) ES2462522T3 (es)
IL (1) IL222851A0 (es)
MA (1) MA34939B1 (es)
MX (1) MX2012012960A (es)
PE (1) PE20130228A1 (es)
SG (1) SG185459A1 (es)
TN (1) TN2012000531A1 (es)
TW (1) TW201200510A (es)
UY (1) UY33369A (es)
WO (1) WO2011141326A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603232B2 (ja) * 2007-05-01 2014-10-08 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ネコ類において骨関節炎を診断するための方法および組成物
US8796253B2 (en) * 2007-05-18 2014-08-05 Bayer Intellectual Property Gmbh Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP5727002B2 (ja) * 2010-05-08 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換ヘテロサイクリルベンジルピラゾール類およびその使用
US9040711B2 (en) 2012-07-02 2015-05-26 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
JP6453218B2 (ja) 2012-08-24 2019-01-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を治療するためのｈｉｆ活性の複素環式修飾物質
US9115120B2 (en) 2012-08-24 2015-08-25 Board Of Regents, The University Of Texas Systems Heterocyclic modulators of HIF activity for treatment of disease
WO2014031928A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
US9663504B2 (en) 2014-02-25 2017-05-30 Board Of Regents, The University Of Texas System Salts of heterocyclic modulators of HIF activity for treatment of disease
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
CN110167916B (zh) * 2017-01-13 2022-11-11 日产化学株式会社 芳香族二胺化合物前体的制造方法
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
CN100387594C (zh) 2003-04-03 2008-05-14 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
US8796253B2 (en) * 2007-05-18 2014-08-05 Bayer Intellectual Property Gmbh Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BRPI0921257A2 (pt) * 2008-11-14 2016-02-23 Bayer Schering Pharma Ag composto de arila heterociclicamente subsittuidos como inibidores hif
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
WO2010054764A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heteroaromatische verbindungen zur verwendung als hif-inhibitoren
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
JP5727002B2 (ja) * 2010-05-08 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換ヘテロサイクリルベンジルピラゾール類およびその使用

Also Published As

Publication number Publication date
UY33369A (es) 2011-12-01
PE20130228A1 (es) 2013-03-15
CR20120570A (es) 2013-04-22
AR081368A1 (es) 2012-08-29
US20120028950A1 (en) 2012-02-02
MX2012012960A (es) 2012-12-17
MA34939B1 (fr) 2014-03-01
CN103003269A (zh) 2013-03-27
JP5727002B2 (ja) 2015-06-03
US8470811B2 (en) 2013-06-25
CA2798375A1 (en) 2011-11-17
EP2569312A1 (de) 2013-03-20
DOP2012000284A (es) 2013-03-31
ECSP12012288A (es) 2012-12-28
TN2012000531A1 (en) 2014-04-01
KR20130108997A (ko) 2013-10-07
TW201200510A (en) 2012-01-01
BR112012028651A2 (pt) 2016-08-09
EP2569312B1 (de) 2014-03-26
ES2462522T3 (es) 2014-05-23
IL222851A0 (en) 2012-12-31
EA201291167A1 (ru) 2013-05-30
AU2011252223A1 (en) 2012-12-06
US20130172311A1 (en) 2013-07-04
CN103003269B (zh) 2015-11-25
CO6640218A2 (es) 2013-03-22
JP2013526497A (ja) 2013-06-24
SG185459A1 (en) 2012-12-28
WO2011141326A1 (de) 2011-11-17

Similar Documents

Publication Publication Date Title
CU20120157A7 (es) Heterociclilbencilpirazoles sustituidos y uso de los mismos
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
GT201500105A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
UY32236A (es) Compuestos de arilo sustituidos y su uso
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
GT201300215A (es) Inhibidores de glucosilceramida sintasa
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
UY31228A1 (es) Ariloxazoles sustituidos y su uso
WO2012143497A3 (de) Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
WO2014153385A3 (en) Methods of treating metabolic disorders
UY33153A (es) Formulación tópica oftálmica de péptidos
BR112012028652A2 (pt) hidroxialquilbenzilpirazois e seu uso
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
WO2012135176A3 (en) The use of wnt agents to prevent hypoxic injury
UA112981C2 (uk) Варіант людського gdnf
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos